Combination therapies with hafnium oxide nanoparticles and PD-l1 antibodies

TW202635314APending Publication Date: 2026-09-01JANSSEN PHARMA NV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114137958
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-29
Filing Date
2025-10-01
Publication Date
2026-09-01

Smart Images

  • Figure TWG2TA001074326_001
    Figure TWG2TA001074326_001
  • Figure TWG2TA001074326_002
    Figure TWG2TA001074326_002
  • Figure TWG2TA001074326_003
    Figure TWG2TA001074326_003
Patent Text Reader

Abstract

Provide herein are methods of treating non-small cell lung cancer (NSCLC) in an individual in need thereof by administering a combination of a nanoparticle composition comprising HfO2, radiation therapy, chemotherapy, and a PD-L1 antibody to the individual. Also provided are methods of selecting an individual for treatment of NSCLC according to the methods provided herein.
Need to check novelty before this filing date? Find Prior Art